Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
25,174,714
-
Share change
-
-2,086,952
-
Total reported value
-
$21,025,121
-
Put/Call ratio
-
0%
-
Price per share
-
$0.83
-
Number of holders
-
32
-
Value change
-
-$1,747,004
-
Number of buys
-
10
-
Number of sells
-
24
Institutional Holders of CTI BIOPHARMA CORP - COM (CTIC) as of Q3 2019
As of 30 Sep 2019,
CTI BIOPHARMA CORP - COM (CTIC) was held by
32 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
25,174,714 shares.
The largest 10 holders included
BVF INC/IL, ORBIMED ADVISORS LLC, NEA Management Company, LLC, Stonepine Capital Management, LLC, RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., CAXTON CORP, and JPMORGAN CHASE & CO.
This page lists
32
institutional shareholders reporting positions in this security
for the Q3 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.